Gilead Withdraws Request for Special Orphan Status on Experimental Coronavirus Treatment

Critics said the company was profiteering from the coronavirus pandemic by seeking tax and monopoly benefits under a program intended to encourage drug development for rare diseases.

from NYT > Health https://ift.tt/2JfkIci
via health&fitness